
{
  "documentMetadata": {
    "title": "Pneumonia caused by Streptococcus pneumoniae",
    "sourceFile": "Pneumonia, Streptococcus pneumoniae.pdf",
    "lastUpdated": "2025-04-22"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Specific therapy for S. pneumoniae.",
        "Blood or sputum culture positive for S. pneumoniae or positive urinary antigen or positive nucleic acid amplification test (NAAT)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Streptococcus pneumoniae"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "For penicillin-susceptible organism (MIC ≤2 µg/mL):"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "condition": "IV regimens",
            "components": [
              {
                "drug": "Penicillin G",
                "dose": "2 million U",
                "route": "IV",
                "frequency": "q4h"
              },
              {
                "drug": "Ceftriaxone",
                "dose": "2gm",
                "route": "IV",
                "frequency": "q24h",
                "connector": "or"
              },
              {
                "drug": "Cefotaxime",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q8h",
                "notes": "(where available)"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "condition": "Oral regimens",
            "components": [
              {
                "drug": "Amoxicillin",
                "dose": "1 gm",
                "route": "po",
                "frequency": "tid"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "condition": "Penicillin-allergic patient",
            "components": [
              {
                "drug": "Doxycycline",
                "dose": "100 mg",
                "route": "po",
                "frequency": "bid",
                "notes": "(document susceptibility especially if the strain is intermediate or resistant to penicillin)"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "For penicillin-resistant or intermediate organism (MIC >2 µg/mL)"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Ceftriaxone",
                "dose": "2gm",
                "route": "IV",
                "frequency": "q24h",
                "connector": "or"
              },
              {
                "drug": "Cefotaxime",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q8h",
                "notes": "(where available)"
              },
              {
                "drug": "Ceftaroline",
                "dose": "600 mg",
                "route": "IV",
                "frequency": "q12h"
              },
              {
                "drug": "Vancomycin",
                "dose": "15-20 mg/kg",
                "frequency": "q8-12h",
                "notes": "(may be preferred if penicillin MIC >4 µg/mL)"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Therapy"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "condition": "Penicillin susceptible, intermediate, or resistant strains (high level)",
        "components": [
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "po/IV",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Moxifloxacin",
            "dose": "400 mg",
            "route": "po/IV"
          },
          {
            "drug": "Linezolid",
            "dose": "600 mg",
            "route": "po/IV",
            "frequency": "q12h"
          },
          {
            "drug": "Clindamycin",
            "dose": "600 mg",
            "route": "IV",
            "frequency": "q8h",
            "notes": "(document susceptibility if strain is intermediate or resistant to penicillin)"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Treat until patient is afebrile, 3-5 days (minimum of 5 days therapy). Because of increasing resistance, confirm susceptibility if a macrolide is used.",
        "Increasing resistance to beta-lactams and macrolides, particularly to the latter in Europe (Curr Opin Pulm Med 19:209, 2013).",
        "For current CDC recommendations for pneumococcal vaccines click here.",
        "For further details on vaccination see: Pneumococcal Vaccines, Adult"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Use of adjunctive corticosteroids limited to severe CAP. See Comments, Community-acquired Pneumonia for definition of severe CAP and dosing.",
        "An observational study (Clin Infect Dis 2022; 75:2219) found that in patients with pneumonia and pneumococcal bacteremia the addition for as few as two days of azithromycin to a beta-lactam reduced the odds for mortality by 45%.",
        "Pneumococcus is identified in 10-15% of the patients with pneumonia. As the etiologic prevalence of Strep. pneumoniae has deceased over the years the frequency of respiratory viruses (25%) has increased (Clin Infect Dis 2017; 65:1736)."
      ]
    }
  ]
}
